Clinical trials: latest news

Clinical trials resources

  • Clinical trials

    A clinical trial is a study in which a new treatment is assessed.There are legal requirements on how a trial should be run.If you choose to join a...

    From: Factsheets

    Information level Level 2
  • Thinking about joining a clinical trial?

    Before you make a decision about joining a clinical trial, make sure you fully understand what’s involved.There will be benefits and risks to joining any clinical trial.Discuss...

    From: Factsheets

    Information level Level 2

Clinical trials features

Clinical trials in your own words

Clinical trials news from aidsmap

More news

Clinical trials news selected from other sources

  • The FDA Should Approve Drugs Based on Evidence, Not Emotions

    A new bill and Donald Trump could come together to undermine the FDA’s ability to safeguard the public from dangerous new drugs.

    15 December 2016 | Slate
  • Winners and Losers in the 21st Century Cures Act

    Obama signs the biggest health legislation since the Affordable Care Act. What strings are attached?

    15 December 2016 | Poz
  • Trump is considering a dangerous radical to lead FDA. Here’s why that’s bad news.

    Imagine being prescribed a medicine when neither your doctor nor the manufacturer has any clue whether it will actually work — because the government never required it to be tested for effectiveness.

    12 December 2016 | STAT
  • NHS England fudges PrEP access and delays on-demand access to PrEP by years; blocks doctors from prescribing PrEP now

    It is difficult to be impressed with this compromise. Rather than meet the real need of people currently at highest risk, it will further delay access to an option to prevent HIV transmission that has clearly passed the criteria for safety, efficacy and effectiveness laid out for other NHS treatments.

    04 December 2016 | HIV i-Base
  • Ageing positively: the menopause in women living with HIV

    Our team is conducting one of the largest studies to date in Europe, and the first ever in the UK, looking at how the menopause affects the health and wellbeing of women living with HIV.

    02 December 2016 | National Institute for Health Research
  • Could the FDA be dismantled under Trump?

    Has President-elect Donald Trump put a bull’s-eye on the Food and Drug Administration? The agency is facing post-election upheaval. Public health advocates are bracing for a seismic shift: a surrender of the agency’s rules for off-label promotion of drugs; the importation of more drugs from other countries; and fewer requirements for clinical trials.

    22 November 2016 | STAT
  • DISCOVER Trial Factsheet

    Fact sheet explaining the background to the DISCOVER trial

    17 November 2016 | AIDS Foundation of Chicago
  • Community demand for temporary halt to Gilead DISCOVER study

    A group of U.S., Canadian, and European community advocates and HIV NGO workers have written a letter exrpesing "deep dismay" that Gilead Sciences have proceeded with the DISCOVER trial PrEP"without engaging stakeholders in a substantial or meaningful way.". DISCOVER will compared Gilead's new comination pill, Descovy against Truvada as PrEP. In 2007, the HIV/AIDS field adopted Good Participatory Practice (GPP), a formal set of guidelines approved by UNAIDS for stakeholder engagement in HIV prevention clinical trials. "It is astonishing," says the letter, "that Gilead has failed to follow GPP guidelines in the design and implementation of DISCOVER, since GPP was developed partly as a response to the failure of previous prevention trials involving tenofovir."

    17 November 2016 | HIV Prevention Justice Alliance
  • Why Are HIV Groups Charging Gilead With Bad Behavior in New PrEP Trial?

    Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial, and we are among a coalition of HIV activists and organizations from Europe and North America calling them out on their bad corporate behavior. We root our criticism in the Good Participatory Practice (GPP) guidelines that were inspired, in part, by controversies in earlier PrEP trials.

    17 November 2016 | The Body
  • Statement on DISCOVER Study of F/TAF for PrEP

    Gilead Sciences released this statement after considerable interest and concerns abut the forthcoming study of their new tenofovir formulation, TAF, for use in PrEP. The TAF/FTC pill is called Descovy(R). "Gilead Sciences is sponsoring a clinical trial, known as the DISCOVER study, to test whether a combination of emtricitabine and tenofovir alafenamide (F/TAF) is as safe and effective as Truvada® (emtricitabine and tenofovir disoproxil fumarate, F/TDF) at reducing the risk of HIV infection when used as pre-exposure prophylaxis (PrEP). F/TAF was recently approved for HIV treatment, but it is not yet known whether it is effective as PrEP...."

    16 November 2016 | Gilead Sciences
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.